GMP vs EU GMP: What Is the Difference for Extraction Facilities?
GMP is the general principle of controlled, documented manufacturing. EU GMP is the specific European implementation of it, published in EudraLex Volume 4 and enforced by national competent authorities. For an extraction facility the practical differences are Qualified Person certification downstream, EU-specific qualification expectations, and inspection against the European text.
If you are specifying equipment for a facility that may one day supply the European market, the distinction affects documentation scope more than it affects the hardware itself. Our guide to what EU GMP asks of extraction equipment covers the hardware side in full; this article covers the regulatory difference. If you are still choosing an extraction method, hydrocarbon vs ethanol vs CO2 for EU GMP facilities compares the three on compliance burden.
GMP is a principle, EU GMP is a rulebook
"GMP" on its own describes an approach: manufacture under controlled conditions, document what you did, and be able to prove it afterwards. Almost every regulated market has its own codification of that idea — US cGMP under 21 CFR Parts 210 and 211, WHO GMP, and the PIC/S guide among them.
EU GMP is the European version, and it is a specific published text rather than a general expectation. When a buyer says "we need EU GMP," they mean the facility will be inspected against that text by a European competent authority.
The difference matters commercially because "GMP-compliant" is a claim anyone can make loosely. "Inspected against EudraLex Volume 4 by a named competent authority" is not. If a supplier or a partner uses the two interchangeably, that is worth probing — we covered the pattern in detail in GMP greenwashing in cannabis extraction equipment.
The Qualified Person is the clearest structural difference
The requirement with no close equivalent in most other frameworks is the Qualified Person. In the EU, a named, legally accountable individual must certify each batch of a finished medicinal product before it is released to market, confirming it was manufactured and checked in accordance with GMP and the marketing authorisation.
It is worth being precise about who does this. An extraction facility producing an active substance does not perform QP certification itself — that step sits with the medicinal-product manufacturer or importer downstream. What matters upstream is that the QP's decision depends on being able to rely on the GMP status of the active substance and the records behind it.
So the practical effect on an extraction operation is indirect but real: batch records, deviation handling and equipment logs stop being internal housekeeping and become evidence that someone outside your company has to be able to rely on. The working test is whether an external party could reconstruct what happened to a batch from your documentation alone, without asking you.
Part I, Part II, and where extract sits
EU GMP splits into Part I for finished medicinal products and Part II for active substances. A cannabis extract used as an active ingredient generally falls under Part II, with Part I applying once it is formulated into a dosage form.
This matters when scoping equipment. A facility producing extract as an API has a different qualification burden from one producing finished dosage forms on the same site, and the boundary between the two determines where your validated processes have to end.
Classification is not a decision you make unilaterally. It follows from the product, its intended use and the applicable marketing authorisation, and it is confirmed with the competent authority — so establish it with your regulatory advisor early, because it sets the scope of everything downstream.
What actually changes on the production floor
Less than most people expect, in hardware terms. A well-built extraction system suited to US cGMP work is usually suited to EU GMP work as well. What changes is the depth of evidence around it:
- Qualification is more explicitly prescribed. Annex 15 sets out expectations for qualification and validation that need to be planned before installation, not reconstructed afterwards.
- Computerised systems get specific attention. Annex 11 covers audit trails, access control and data integrity for the control systems on your distillation and extraction equipment.
- Change control tightens. Swapping a gasket material or a filter medium becomes a documented change rather than a maintenance decision, which is why sourcing consistent machine parts and filter media matters more than it first appears.
What stays the same
The engineering fundamentals do not change between frameworks. Hygienic product-contact surfaces, drainable geometry, traceable materials of construction and reliable batch data serve you under any GMP regime. Equipment chosen well for one is rarely wrong for the other — which is why the sensible strategy is to specify to the stricter documentation requirement from the start, even if your first market does not demand it.
The same is true of cleanability and sanitary design, which is the requirement hardest to retrofit after delivery and identical in principle under either framework.
It is also worth repeating that neither framework certifies a machine. Certificates go to sites. Decimal does not hold an EU GMP certificate: that certification applies to medicinal-product manufacturing sites, not to equipment or to the companies that build it.
Specifying for the stricter standard
If EU supply is a possibility, build the documentation requirement into the purchase rather than the retrofit. Documentation packages to support IQ/OQ/PQ and facility turnover are available, with scope varying by model and configuration.
The practical sequence is to settle the extraction method first, then evaluate specific systems against it. Hydrocarbon vs ethanol vs CO2 for EU GMP facilities handles the first decision; how to evaluate extraction equipment for EU GMP readiness handles the second.
FAQ
Is EU GMP stricter than US cGMP?
They are different rather than simply ranked. Both require controlled, documented manufacturing. EU GMP is more explicit in some areas — notably the Qualified Person role, Annex 15 qualification expectations and Annex 11 computerised systems — and it is enforced by European competent authorities against a specific published text. In practice, specifying to EU documentation expectations will generally satisfy cGMP documentation expectations as well.
Does an extraction facility need its own Qualified Person?
Not for the extraction step itself. QP certification applies to batch release of a finished medicinal product, which sits with the medicinal-product manufacturer or importer downstream. What an extraction facility needs is documentation robust enough that the downstream QP can rely on it.
Can extraction equipment be EU GMP certified?
No. Certificates are issued to sites following inspection, not to machines. Equipment can be designed and documented to support a site's certification, but any supplier describing a machine itself as "EU GMP certified" is misusing the term.
Does my extract fall under Part I or Part II?
A cannabis extract used as an active substance generally falls under Part II, with Part I applying once it is formulated into a finished dosage form. This is not a self-assessment: it follows from the product, its intended use and the marketing authorisation, and should be confirmed with your regulatory advisor and the competent authority.
Do I need different equipment for EU GMP than for US cGMP?
Usually not. The hardware requirements are broadly common — hygienic product-contact surfaces, drainable geometry, traceable materials and reliable batch data. What differs is the depth of documentation and the formality of qualification and change control around the same machine.
Talk to engineering before you specify
Read EU GMP Cannabis Extraction Equipment: Complete Guide for the equipment-level detail, then contact our engineering team to confirm what documentation ships with the configuration you are considering, or request a quote for a specific setup.